Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders

Journal of Clinical Investigation

Volumn 117, Issue 12, 2007, Pages 3603-3609

  Drenth, Joost P H ^a   Waxman, Stephen G ^b,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; LIDOCAINE; LOCAL ANESTHETIC AGENT; MEXILETINE; PHENYTOIN; PROSTAGLANDIN; SEROTONIN; VOLTAGE GATED SODIUM CHANNEL;

ACTION POTENTIAL; ALPHA CHAIN; ANALGESIA (SENSORY DYSFUNCTION); CHANNELOPATHY; DRUG MECHANISM; ERYTHROMELALGIA; GENE FUNCTION; GENE LOCATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC POLYMORPHISM; HUMAN; MISSENSE MUTATION; MUTATOR GENE; NERVE CELL; NEUROPATHIC PAIN; NOCICEPTION; NOCICEPTIVE RECEPTOR; NONHUMAN; PAIN; PAROXYSMAL EXTREME PAIN DISORDER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SCN1A GENE; SCN2A GENE; SCN3A GENE; SCN9A GENE; SPINAL GANGLION;

ACTION POTENTIALS; HUMANS; MUTATION, MISSENSE; NEURONS; PAIN; PAIN INSENSITIVITY, CONGENITAL; PERIPHERAL NERVES; SODIUM CHANNELS;

EID: 36849036949     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI33297     Document Type: Review

References (63)

1. Zubieta, J.K., et al. 2003. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 299:1240-1243.
2. Ophoff, R.A., et al. 1996. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 87:543-552.
3. Yang, Y., et al. 2004. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J. Med. Genet. 41:171-174.
4. Drenth, J.P., et al. 2005. SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels. J. Invest. Dermatol. 124:1333-1338.
5. Han, C., et al. 2006. Sporadic onset of erythermalgia: a gain-of-function mutation in Nav1.7. Ann. Neurol. 59:553-558.
6. Harty, T.P., et al. 2006. Na(V)1.7 mutant A863P in erythromelalgia: effects of altered activation and steady-state inactivation on excitability of nociceptive dorsal root ganglion neurons. J. Neurosci. 26:12566-12575.
7. Fertleman, C.R., et al. 2006. SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes. Neuron. 52:767-774.
8. Cox, J.J., et al. 2006. An SCN9A channelopathy causes congenital inability to experience pain. Nature. 444:894-898.
9. Waxman, S.G. 2006. Neurobiology: a channel sets the gain on pain. Nature. 444:831-832.
10. Catterall, W.A., Goldin, A.L., and Waxman, S.G. 2005. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol. Rev. 57:397-409.
11. Waxman, S.G. 2000. The neuron as a dynamic electrogenic machine: modulation of sodium-channel expression as a basis for functional plasticity in neurons. Philos. Trans. R. Soc. Lond. B Biol. Sci. 355:199-213.
12. Catterall, W.A. 2000. Structure and regulation of voltage-gated Ca2+ channels. Annu. Rev. Cell Dev. Biol. 16:521-555.
13. George, A.L., Jr. 2005. Inherited disorders of voltage-gated sodium channels. J. Clin. Invest. 115:1990-1999.
14. Meisler, M.H., and Kearney, J.A. 2005. Sodium channel mutations in epilepsy and other neurological disorders. J. Clin. Invest. 115:2010-2017.
15. Klugbauer, N., Lacinova, L., Flockerzi, V., and Hofmann, F. 1995. Structure and functional expression of a new member of the tetrodotoxin- sensitive voltage-activated sodium channel family from human neuroendocrine cells. EMBO J. 14:1084-1090.
16. Toledo-Aral, J.J., et al. 1997. Identification of PN1, a predominant voltage-dependent sodium channel expressed principally in peripheral neurons. Proc. Natl. Acad. Sci. U. S. A. 94:1527-1532.
17. Djouhri, L., et al. 2003. Sensory and electrophysiological properties of guinea-pig sensory neurones expressing Nav 1.7 (PN1) Na+ channel alpha subunit protein. J. Physiol. 546:565-576.
18. Fang, X., et al. 2002. The presence and role of the tetrodotoxin- resistant sodium channel Na(v)1.9 (NaN) in nociceptive primary afferent neurons. J. Neurosci. 22:7425-7433.
19. Djouhri, L., et al. 2003. The TTX-resistant sodium channel Nav1.8 (SNS/PN3): expression and correlation with membrane properties in rat nociceptive primary afferent neurons. J. Physiol. 550:739-752.
20. Cummins, T.R., Howe, J.R., and Waxman, S.G. 1998. Slow closed-state inactivation: a novel mechanism underlying ramp currents in cells expressing the hNE/PN1 sodium channel. J. Neurosci. 18:9607-9619.
21. Renganathan, M., Cummins, T.R., and Waxman, S.G. 2001. Contribution of Na(v)1.8 sodium channels to action potential electrogenesis in DRG neurons. J. Neurophysiol. 86:629-640.
22. England, S., Bevan, S., and Docherty, R.J. 1996. PGE2 modulates the tetrodotoxin-resistant sodium current in neonatal rat dorsal root ganglion neurones via the cyclic AMP-protein kinase A cascade. J. Physiol. 495:429-440.
23. Gold, M.S., Reichling, D.B., Shuster, M.J., and Levine, J.D. 1996. Hyperalgesic agents increase a tetrodotoxin-resistant Na+ current in nociceptors. Proc. Natl. Acad. Sci. U. S. A. 93:1108-1112.
24. Okamoto, K., et al. 2002. 5-HT2A receptor subtype in the peripheral branch of sensory fibers is involved in the potentiation of inflammatory pain in rats. Pain. 99:133-143.
25. Black, J.A., Liu, S., Tanaka, M., Cummins, T.R., and Waxman, S.G. 2004. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. Pain. 108:237-247.
26. Nassar, M.A., et al. 2004. Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. Proc. Natl. Acad. Sci. U. S. A. 101:12706-12711.
27. Nassar, M.A., Levato, A., Stirling, L.C., and Wood, J.N. 2005. Neuropathic pain develops normally in mice lacking both Nav1.7 and Nav1.8. Mol. Pain. 1:24.
28. Laird, J.M., Souslova, V., Wood, J.N., and Cervero, F. 2002. Deficits in visceral pain and referred hyperalgesia in Nav1.8 (SNS/PN3)-null mice. J. Neurosci. 22:8352-8356.
29. Drenth, J.P., and Michiels, J.J. 1990. Three types of erythromelalgia [editorial]. BMJ. 301:454-455.
30. Michiels, J.J., Van Joost, T., and Vuzevski, V.D. 1989. Idiopathic erythermalgia: a congenital disorder. J. Am. Acad. Dermatol. 21:1128-1130.
31. Drenth, J.P., and Michiels, J.J. 1994. Erythromelalgia and erythermalgia: diagnostic differentiation. Int. J. Dermatol. 33:393-397.
32. Drenth, J.P., et al. 1996. Cutaneous pathology in primary erythermalgia. Am. J. Dermatopathol. 18:30-34.
33. van Genderen, P.J., Michiels, J.J., and Drenth, J.P. 1993. Hereditary erythermalgia and acquired erythromelalgia. Am. J. Med. Genet. 45:530-532.
34. Kirby, R.L. 1987. Erythromelalgia - not so benign [letter]. Arch. Phys. Med. Rehabil. 68:389.
35. Drenth, J.P., et al. 2001. The primary erythermalgia-susceptibility gene is located on chromosome 2q31-32. Am. J. Hum. Genet. 68:1277-1282.
36. Dib-Hajj, S.D., et al. 2005. Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain. 128:1847-1854.
37. Michiels, J.J., te Morsche, R.H., Jansen, J.B., and Drenth, J.P. 2005. Autosomal dominant erythermalgia associated with a novel mutation in the voltage-gated sodium channel alpha subunit Nav1.7. Arch. Neurol. 62:1587-1590.
38. Choi, J.S., Dib-Hajj, S.D., and Waxman, S.G. 2006. Inherited erythermalgia. Limb pain from an S4 charge-neutral Na channelopathy. Neurology. 67:1563-1567.
39. Lampert, A., Dib-Hajj, S.D., Tyrrell, L., and Waxman, S.G. 2006. Size matters: Erythromelalgia mutation S241T in Nav1.7 alters channel gating. J. Biol. Chem. 281:36029-36035.
40. Lee, M.J., et al. 2007. Characterization of a familial case with primary erythromelalgia from Taiwan. J. Neurol. 254:210-214.
41. Zhang, L.L., et al. 2007. Mutation hotspots of SCN9A in primary erythermalgia. Br. J. Dermatol. 156:767-769.
42. Cummins, T.R., Dib-Hajj, S.D., and Waxman, S.G. 2004. Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy. J. Neurosci. 24:8232-8236.
43. Rush, A.M., et al. 2006. A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. Proc. Natl. Acad. Sci. U. S. A. 103:8245-8250.
44. Waxman, S.G., and Dib-Hajj, S.D. 2005. Erythromelalgia: a hereditary pain syndrome enters the molecular era. Ann. Neurol. 57:785-788.
45. Waxman, S.G. 2007. Channel, neuronal and clinical function in sodium channelopathies: from genotype to phenotype. Nat. Neurosci. 10:405-409.
46. Hayden, R., and Grossman, M. 1959. Rectal, ocular, and submaxillary pain; a familial autonomic disorder related to proctalgia fugaz: report of a family. AMA. J. Dis. Child. 97:479-482.
47. Fertleman, C.R., and Ferrie, C.D. 2006. What's in a name--familial rectal pain syndrome becomes paroxysmal extreme pain disorder. J. Neurol. Neurosurg. Psychiatr. 77:1294-1295.
48. Bednarek, N., et al. 2005. Familial rectal pain: a familial autonomic disorder as a cause of paroxysmal attacks in the newborn baby. Epileptic Disord. 7:360-362.
49. Mann, T.P., and Cree, J.E. 1972. Familial rectal pain. Lancet. 1:1016-1017.
50. Dugan, R.E. 1972. Familial rectal pain. Lancet. 1:854.
51. Fertleman, C.R., et al. 2007. Paroxysmal extreme pain disorder (previously familial rectal pain syndrome). Neurology. 69:586-595.
52. Lai, J., Porreca, F., Hunter, J.C., and Gold, M.S. 2004. Voltage-gated sodium channels and hyperalgesia. Annu. Rev. Pharmacol. Toxicol. 44:371-397.
53. Silverman, F.N., and Gilden, J. 1959. Congenital insensitivity to pain: a neurologic syndrome with bizarre skeletal lesions. Radiology. 72:176-190.
54. Goldberg, Y., et al. 2007. Loss-of-function mutations in the Na(v)1.7 gene underlie congenital indifference to pain in multiple human populations. Clin. Genet. 71:311-319.
55. Ahmad, S., et al. 2007. A stop codon mutation in SCN9A causes lack of pain sensation. Hum. Mol. Genet. 16:2114-2121.
56. Han, C., et al. 2007. Temperature dependence of erythromelalgia mutation L858F in sodium channel Nav1.7. Mol. Pain. 3:3.
57. Rush, A.M., et al. 2006. Differential modulation of sodium channel Na(v)1.6 by two members of the fibroblast growth factor homologous factor 2 subfamily. Eur. J. Neurosci. 23:2551-2562.
58. Wittmack, E.K., et al. 2004. Fibroblast growth factor homologous factor 2B: association with Nav1.6 and selective colocalization at nodes of Ranvier of dorsal root axons. J. Neurosci. 24:6765-6775.
59. Waxman, S.G., and Dib-Hajj, S. 2005. Erythermalgia: molecular basis for an inherited pain syndrome. Trends Mol. Med. 11:555-562.
60. Legroux-Crespel, E., et al. 2003. Treatment of familial erythermalgia with the association of lidocaine and mexiletine [In French]. Ann. Dermatol. Venereol. 130:429-433.
61. Sheets, P.L., Jackson, J.O., Waxman, S.G., Dib-Hajj, S.D., and Cummins, T.R. 2007. A Nav1.7 channel mutation associated with hereditary erythromelalgia contributes to neuronal hyperexcitability and displays reduced lidocaine sensitivity. J. Physiol. 581:1019-1031.
62. Cohen, J.S. 2000. Erythromelalgia: new theories and new therapies. J. Am. Acad. Dermatol. 43:841-847.
63. Firmin, D., et al. 2007. Treatment of familial erythromelalgia with venlafaxine. J. Eur. Acad. Dermatol. Venereol. 21:836-837.